Maike Windbergs: Through ENABLE, we want to learn to understand better the interfaces between infection, inflammation and immune responses in order to develop new approaches for diseases that are not yet curable in an adequate manner.
Ivan Đikić: COVID-19 is a good example here – severe courses of the disease are often accompanied by an excessive immune reaction, where the immune system ultimately attacks and destroys the body’s own tissue.
Windbergs: Even though we are both working in basic research, our training as physician and pharmacist, respectively, was guided by our aspiration to solve some of the greatest biomedical challenges of our times. This can only be achieved in an interdisciplinary consortium, which is why it’s important to assemble a team of different specialists in order to find completely new research approaches.
Đikić: This project enables us to further expand the platform technologies already available and to use them in such a way that new findings can be rapidly transferred into a clinical context. Apart from the fact that we are making an important contribution to new therapeutic strategies with this, we are also making a significant contribution to training a new generation of interdisciplinary researchers for the future.
Windbergs: A major challenge, of course, lies in understanding the interfaces and interaction between different mechanisms in the human body and in developing suitable tools and models – for example, 3D models from human tissue. With such models, we systematically mimic the situation in the human body in order to enable transferability to clinical practice. In this way, we can, for example, develop targeted strategies for highly effective antibiotics and antivirals.
Đikić: At the end of the day, however, we never know all the obstacles that will stand in our way in a project. To a certain extent, that is also the special scientific appeal – we are moving in new territory, and there are always surprising discoveries and equally unexpected challenges. Having the right team and the right infrastructure is therefore essential so that we can react flexibly and quickly to new findings.
Windbergs: A formative experience for all of us was certainly how the platform technology developed in Mainz for the production of mRNA-based vaccines led to the development of effective COVID-19 vaccines in record time. As far as my own laboratory is concerned, the special thing for me is our successful replication of viable 3D human tissues, which we can also use to simulate diseases. These will be extremely valuable in our envisaged projects for exploring mechanisms and validating therapeutic strategies in the context of tissue.
Đikić: A few years ago, my laboratory made a groundbreaking discovery when we successfully shed light on a previously unknown type of ubiquitin modification through Legionella enzymes. Using a whole repertoire of structural and functional studies enabled us to explain and understand both molecular details as well as the processes involved in the cellular context of a Legionella infection. This broad spectrum of methods, which we are meanwhile also combining with bioinformatics methods, for example dynamic modelling, has become an indispensable tool for the future. With our PROXIDRUGS cluster, we have also laid the foundation for the first time for the development of molecules that could also be used in therapeutics.